Cartesian Therapeutics (RNAC) Preferred Stock Liabilities (2015 - 2023)
Cartesian Therapeutics (RNAC) posted quarterly Preferred Stock Liabilities of $296.9 million for Q4 2023, up 5837.02% quarter-over-quarter from $5.0 million in Q2 2016.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) Preferred Stock Liabilities (2015 - 2023) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Preferred Stock Liabilities for 3 consecutive years, with $296.9 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Preferred Stock Liabilities changed N/A year-over-year to $296.9 million; the TTM figure through Dec 2023 stood at $296.9 million (changed N/A YoY), while the FY2023 annual figure was $296.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities rose to $296.9 million in Q4 2023 per RNAC's latest filing, from $5.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $296.9 million in Q4 2023 and bottomed at $296.9 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Cartesian Therapeutics | 271.98 Mn | 271.98 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 296.85 Mn |
| Jun 30, 2016 | 5.00 Mn |
| Dec 31, 2015 | 137.48 Mn |